Diplomat Pharmacy (DPLO) Misses Q3 EPS by 22c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Diplomat Pharmacy (DPLO) PT Lowered to $18 at Mizuho Securities
November 8, 2018 10:49 AM ESTMizuho Securities analyst Ann Hynes lowered the price target on Diplomat Pharmacy (NYSE: DPLO) to $18.00 (from $23.00) while maintaining a Neutral rating.
Hynes commented, "We are updating our model and price target (now $18 from $23). Despite yesterday's sell-off driven by the disclosure of significant... More
